NCT05139017 2026-03-10
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
Clinical Trials
20 trialsNCT04542824 2026-03-03
EPCOREā¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-03-03
EPCOREā¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT06508658 2026-03-03
EPCORE DLBCL-4
Genmab
Phase 3 Recruiting
NCT06806033 2026-03-02
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT07409428 2026-02-13
A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Not yet recruiting
NCT04384484 2026-01-26
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04408638 2026-01-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT07124936 2025-08-15
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06854445 2025-03-24
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
NCT03488251 2022-08-16
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Molecular Templates, Inc.
Phase 2 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT00436280 2020-08-06
Chemotherapy for Participants With Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT04500561 2020-08-05
YY-20394 ćGEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed